Azitra Inc (AZTR) Actualités

Form 8-K - Current report

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates PR Newswire BRANFORD, Conn...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Azitra to Present at BIO-Europe 2024

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Azitra to Participate in the 2024 Maxim Healthcare Virtual Summit

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Form ARS - Annual Report to Security Holders

Form DEF 14A - Other definitive proxy statements

Azitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology Congress

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Azitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR Inhibitors

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...

Form 144 - Report of proposed sale of securities

Azitra to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an...

Azitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b...

Azitra Receives Study May Proceed letter from the FDA for IND to Treat Skin Rash from EGFR Inhibitors

New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe...

Azitra Announces First Patient Screened and Scheduled to Enroll in Phase 1b Trial of ATR-12 for Netherton Syndrome

Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b...

Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision...